文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

乌布格列净：首次批准。

Ubrogepant: First Approval.

机构信息

Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

出版信息

Drugs. 2020 Feb;80(3):323-328. doi: 10.1007/s40265-020-01264-5.

DOI:10.1007/s40265-020-01264-5
PMID:32020557
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7062659/
Abstract

Ubrogepant (Ubrelvy™) is an orally administered, small molecule, highly-selective, calcitonin gene-related peptide (CGRP) antagonist that was developed by Allergan under license to Merck & Co. as an acute treatment for migraine. In December 2019, ubrogepant received its first global approval in the USA for the acute treatment of migraine (± aura) in adults. This article summarizes the milestones in the development of ubrogepant leading to its first global approval for the acute treatment of migraine (± aura) in adults.

摘要

乌布列泮（Ubrelvy™）是一种经口给予的、小分子的、高选择性的降钙素基因相关肽（CGRP）拮抗剂，由 Allergan 公司授权 Merck & Co. 开发，作为偏头痛的急性治疗药物。2019 年 12 月，乌布列泮在美国首次获得全球批准，用于成人偏头痛（伴或不伴先兆）的急性治疗。本文总结了乌布列泮开发过程中的重要里程碑，最终使其在全球范围内首次获批用于成人偏头痛（伴或不伴先兆）的急性治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29b8/7062659/25deb032cb59/40265_2020_1264_Figb_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29b8/7062659/0c085e830b98/40265_2020_1264_Figa_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29b8/7062659/25deb032cb59/40265_2020_1264_Figb_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29b8/7062659/0c085e830b98/40265_2020_1264_Figa_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/29b8/7062659/25deb032cb59/40265_2020_1264_Figb_HTML.jpg

相似文献

[1]
Ubrogepant: First Approval.

Drugs. 2020-2

[2]
Ubrogepant for the treatment of migraine.

Expert Opin Pharmacother. 2020-2-3

[3]
Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine: A meta-analysis.

Medicine (Baltimore). 2021-2-26

[4]
Ubrogepant to treat migraine.

Drugs Today (Barc). 2020-7

[5]
Atogepant: First Approval.

Drugs. 2022-1

[6]
Ubrogepant for the Treatment of Migraine.

N Engl J Med. 2019-12-5

[7]
Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans.

Headache. 2020-7

[8]
Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial.

Headache. 2020-1

[9]
The Emperor's New Gepants: Are the Effects of the New Oral CGRP Antagonists Clinically Meaningful?

Headache. 2019-1

[10]
Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome: Results From the Randomized PRODROME Trial.

Neurology. 2024-9-24

引用本文的文献

[1]
Determinants of Improved CGRP Peptide Binding Kinetics Revealed by Enhanced Molecular Simulations.

bioRxiv. 2025-6-17

[2]
Gepants in Primary Care: A Targeted Approach to Acute and Preventive Treatment of Migraine.

Pain Ther. 2025-6-27

[3]
A 2-Part, Open-Label, Phase 1 Bioequivalence and Food-Effect Study of Ubrogepant in Healthy Adult Participants.

Clin Pharmacol Drug Dev. 2025-7

[4]
Head-to-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatment.

Pain Manag. 2025-5

[5]
CGRP promotes osteogenic differentiation by regulating macrophage M2 polarization through HDAC6/AKAP12 signaling pathway.

Regen Med. 2024

[6]
Migraine and Its Treatment from the Medicinal Chemistry Perspective.

ACS Pharmacol Transl Sci. 2024-3-16

[7]
Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials.

J Headache Pain. 2024-2-5

[8]
A Comprehensive Review of the Mechanism, Efficacy, Safety, and Tolerability of Ubrogepant in the Treatment of Migraine.

Cureus. 2023-11-2

[9]
Consensus-Based Recommendations on the Use of CGRP-Based Therapies for Migraine Prevention in the UAE.

Neurol Ther. 2023-12

[10]
Research Progress in Calcitonin Gene-Related Peptide and Bone Repair.

Biomolecules. 2023-5-15

本文引用的文献

[1]
Long-Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52-Week Extension Trial.

Headache. 2020-1

[2]
Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males.

Clin Transl Sci. 2020-5

[3]
Ubrogepant for the Treatment of Migraine.

N Engl J Med. 2019-12-5

[4]
Making Better Dose Decisions: Using Exposure-Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment.

Clin Transl Sci. 2020-5

[5]
Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.

JAMA. 2019-11-19

[6]
Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries.

Cephalalgia. 2020-4

[7]
Single Therapeutic and Supratherapeutic Doses of Ubrogepant Do Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized Trial.

Clin Pharmacol Ther. 2019-12-14

[8]
Recent Advances in Pharmacotherapy for Episodic Migraine.

CNS Drugs. 2019-11

[9]
Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults.

Cephalalgia. 2019-9-19

[10]
CGRP as the target of new migraine therapies - successful translation from bench to clinic.

Nat Rev Neurol. 2018-6

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索